<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Telavancin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Telavancin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Telavancin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12310" href="/d/html/12310.html" rel="external">see "Telavancin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F11238847"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Moderate to severe renal impairment:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Patients with preexisting moderate to severe renal impairment (CrCl ≤50 mL/minute) who were treated with telavancin for hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia had increased mortality observed versus vancomycin. Use of telavancin in patients with preexisting moderate to severe renal impairment (CrCl ≤50 mL/minute) should be considered only when the anticipated benefit to the patient outweighs the potential risk.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Nephrotoxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">New-onset or worsening renal impairment has occurred. Monitor renal function in all patients.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Embryofetal toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">May cause fetal harm. In animal reproduction studies, adverse developmental outcomes were observed in 3 animal species at clinically relevant doses. Verify pregnancy status in females of reproductive potential prior to initiating telavancin. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with telavancin and for 2 days after the final dose.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F8119746"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Vibativ</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871091"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Vibativ [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F8308550"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Glycopeptide</li></ul></div>
<div class="block doa drugH1Div" id="F9739342"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Reserve for patients with or at risk for methicillin-resistant<i> S. aureus </i>(MRSA) infection who cannot receive preferred agents (Chuan 2016; IDSA [Liu 2011]; Rodvold 2014). In patients with CrCl ≤50 mL/minute, decreased efficacy and increased mortality were observed with skin and soft tissue infection and hospital-acquired/ventilator-associated pneumonia, respectively (manufacturer’s labeling).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f9ec9fd-fc1b-4a1f-868a-eeb97c396e6e">Bloodstream infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bloodstream infection (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pathogen-directed therapy for MRSA</i>:<b> IV:</b> 10 mg/kg once daily (IDSA [Liu 2011]; Stryjewski 2014). No maximum dose is recommended by the manufacturer; however, based on limited pharmacokinetic data in patients with obesity, up to 1 g/day may be safely used (Bunnell 2018). Treat uncomplicated <i>S. aureus</i> bacteremia for ≥14 days from day of first negative blood culture, with longer courses warranted for endocarditis or metastatic sites of infection (IDSA [Mermel 2009]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58f09831-e1d9-4d13-a555-4196b8a7ce81">Pneumonia, hospital-acquired or ventilator-associated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, hospital-acquired or ventilator-associated</b>
<b> (alternative agent)</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In patients with CrCl ≤50 mL/minute, increased mortality was observed compared to vancomycin.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>As a component of empiric therapy or pathogen-directed therapy for MRSA:</i>
<b>IV:</b> 10 mg/kg every 24 hours. No maximum dose recommended by the manufacturer; however, based on limited pharmacokinetic data in patients with obesity, up to 1 g/day may be safely used (Bunnell 2018). Duration of therapy varies based on disease severity and response to therapy; treatment is typically given for 7 days (IDSA/ATS [Kalil 2016]; Niederman 2019; Rubinstein 2011; Rubinstein 2014).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In patients with CrCl ≤50 mL/minute, decreased efficacy was observed compared to vancomycin.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 10 mg/kg once daily (IDSA [Liu 2011]; Stryjewski 2012). No maximum dose recommended by the manufacturer; however, based on limited pharmacokinetic data in patients with obesity, up to 1 g/day may be safely used (Bunnell 2018). Total duration of therapy is ≥5 days (including oral step-down therapy); may extend up to 14 days depending on severity and clinical response (IDSA [Stevens 2014]; Spelman 2022).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990892"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Renal function may be estimated using the Cockcroft-Gault formula for dosage adjustment purposes. In patients with CrCl ≤50 mL/min, decreased efficacy and increased mortality were observed with skin and soft tissue infection and hospital-acquired/ventilator-associated pneumonia, respectively.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>US labeling:</i></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;50 mL/minute: No dosage adjustment necessary</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to 50 mL/minute: 7.5 mg/kg every 24 hours</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 10 to &lt;30 mL/minute: 10 mg/kg every 48 hours</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;10 mL/minute: No dosage adjustment provided in manufacturer’s labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">ESRD and hemodialysis patients: No dosage adjustment provided in manufacturer’s labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;50 mL/minute: No dosage adjustment necessary</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to 50 mL/minute: 7.5 mg/kg every 24 hours</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: Not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">ESRD and hemodialysis patients: Not recommended.</p></div>
<div class="block doha drugH1Div" id="F50988155"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild-to-moderate hepatic impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe hepatic impairment (Child-Pugh class C): No dosage adjustment provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F9739346"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F9739198"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Metallic taste (33%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (5% to 27%), vomiting (5% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (8% to 16%; ≥65 years of age: 11%; &lt;65 years of age: 8%), foamy urine (13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness (6%), infusion site pain (4%), rigors (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (3% to 6%), skin rash (4%), localized erythema (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (7%), decreased appetite (3%), abdominal pain (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Infusion site reaction (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal insufficiency (3%; ≥65 years of age: 9%; &lt;65 years of age: 2%), acute renal failure (5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: <i>Clostridioides difficile</i>-associated diarrhea, flushing, hypersensitivity reaction (including anaphylaxis), nephrotoxicity, prolonged QT interval on ECG, transient flushing of upper body, urticaria</p></div>
<div class="block coi drugH1Div" id="F9739191"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to telavancin or any component of the formulation; concomitant use of intravenous unfractionated heparin</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F9739192"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylaxis/hypersensitivity reactions: Serious hypersensitivity reactions, including anaphylaxis, have been reported after first or subsequent doses; some have been fatal. Discontinue if hypersensitivity or rash occurs. Telavancin is a semisynthetic derivative of vancomycin; cross-reactivity rates are unknown. Use with caution in patients with known vancomycin hypersensitivity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac conduction alteration: May prolong QTc interval; avoid use in patients with congenital long QT syndrome, known QTc prolongation, uncompensated heart failure, or severe left ventricular hypertrophy (were excluded from studies); use with caution in patients with concurrent administration of other medications known to prolong the QT interval. Clinical studies indicate mean maximal QTc prolongation of 12 to 15 msec at the end of 10 mg/kg infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reactions: Rapid IV administration may result in flushing, rash, urticaria, and/or pruritus; slowing or stopping the infusion may alleviate these symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrotoxicity: <b>[US Boxed Warning]: New onset or worsening renal impairment has occurred. Monitor renal function prior to, during (at least every 48 to 72 hours; more frequently if indicated), and following therapy in all patients.</b> Usual risk factors include concomitant nephrotoxic medications or baseline comorbidities associated with decreased renal function (eg baseline renal dysfunction, diabetes, hypertension, or heart failure). Contains solubilizer cyclodextrin (hydroxypropyl-beta-cyclodextrin) which may accumulate in patients with renal dysfunction, although the clinical significance of this finding is uncertain (Luke 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: <b>[US Boxed Warning]: In clinical studies, patients with pre-existing moderate-to-severe renal impairment (CrCl ≤50 mL/minute) treated for hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) had increased (all cause) mortality versus vancomycin. Use in HABP/VABP only when benefit outweighs risk.</b> In patients with complicated skin and skin structure infections, efficacy may be reduced in patients with a baseline CrCl ≤50 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Lower doses are often required secondary to age-related decreases in renal function.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pregnancy: <b>[US Boxed Warning]: <b>Based on animal data, may cause fetal harm. Prior to initiating telavancin, </b>
<b>verify pregnancy status in females of reproductive potential. Advise pregnant females of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with telavancin and for 2 days after the final dose.</b></b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Coagulation tests: May interfere with tests used to monitor coagulation (eg, prothrombin time, INR, activated partial thromboplastin time, activated clotting time, coagulation based factor Xa tests) when samples drawn ≤18 hours after drug administration. Blood samples should be collected as close to the next dose of telavancin as possible or a non-phospholipid dependent coagulation test (eg, bleeding time, factor Xa [chromogenic assay], platelet aggregation study, thrombin time) should be used. Consider selecting an alternative anticoagulant not requiring aPTT monitoring; concomitant use of telavancin with IV unfractionated heparin is contraindicated.</p></div>
<div class="block foc drugH1Div" id="F9739353"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vibativ: 750 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vibativ: 750 mg (1 ea [DSC])</p></div>
<div class="block geq drugH1Div" id="F9739185"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F23613347"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Vibativ Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg (per each): $766.29</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871092"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vibativ: 750 mg ([DSC])</p></div>
<div class="block adm drugH1Div" id="F9739348"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Administer IV over 60 minutes. Other medications should not be infused simultaneously through the same IV line. When the same intravenous line is used for sequential infusion of other medications, flush line with D5W, LR, or NS before and after infusing telavancin.</p>
<p style="text-indent:-2em;margin-left:2em;">An infusion reaction (eg, hypotension, maculopapular rash appearing on the face, neck, trunk, and/or upper extremities) may occur if the infusion is too rapid; it is not an allergic reaction. If this should occur, discontinuing or slowing the infusion rate may eliminate these reactions.</p></div>
<div class="block meg drugH1Div" id="F9739184"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedia%2F77801%2Fdownload&amp;token=8RYIFfyLhIBYEqeX7m6uPKsi8zr3SHlezDmBYHBO7hUdT%2BLEN5vHsAl63kvnYFtLrwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=9535" target="_blank">https://www.fda.gov/media/77801/download</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F8308551"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hospital-acquired and ventilator-associated bacterial pneumonia:</b> Treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of <i>Staphylococcus aureus</i> when alternative treatments are not appropriate.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>S</b>
<b>kin and soft tissue infections:</b> Treatment of complicated skin and soft tissue infections caused by susceptible gram-positive organisms including methicillin-susceptible or -resistant <i>S. aureus</i>, vancomycin-susceptible <i>Enterococcus faecalis</i>, and <i>Streptococcus pyogenes</i>, <i>Streptococcus agalactiae</i>, or <i>Streptococcus anginosus</i> group.</p></div>
<div class="block off-label drugH1Div" id="F51439635"><span class="drugH1">Use: Off-Label: Adult</span><p>Bloodstream infection</p></div>
<div class="block mst drugH1Div" id="F8308548"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Telavancin may be confused with telithromycin</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vibativ may be confused with Viactiv, Vibramycin, vigabatrin</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300108"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F9613187"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Telavancin may diminish the therapeutic effect of Anticoagulants. Specifically, telavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Telavancin may diminish the therapeutic effect of Heparin. Specifically, telavancin may artificially increase the results of laboratory tests commonly used to monitor IV heparin effectiveness, which could lead to incorrect decisions to decrease heparin doses. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53623774"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">
<b>[US Boxed Warning]: Verify pregnancy status in females of reproductive potential prior to initiating telavancin. Advise females of reproductive potential <b>to use effective contraception during treatment with telavancin and for 2 days after the final dose.</b></b></p></div>
<div class="block pri drugH1Div" id="F9739188"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Telavancin crosses the placenta (Nanovskaya 2012). <b>[US Boxed Warning]: Telavancin may cause fetal harm. In animal reproduction studies, adverse developmental outcomes were observed in 3 animal species at clinically relevant doses. Advise pregnant women of the potential risk to a fetus.</b></p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to telavancin is ongoing. Health care providers are encouraged to enroll females exposed to telavancin during pregnancy in the Vibativ Pregnancy Registry (1-877-484-2700). Pregnant females may also enroll themselves.</p></div>
<div class="block brc drugH1Div" id="F14456864"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if telavancin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F9739351"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Renal function (prior to start, every 48 to 72 hours; more frequently if indicated, and following therapy). Evaluate pregnancy status prior to use in females of reproductive potential.</p></div>
<div class="block pha drugH1Div" id="F9739219"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Exerts concentration-dependent bactericidal activity; inhibits bacterial cell wall synthesis by blocking polymerization and cross-linking of peptidoglycan by binding to D-Ala-D-Ala portion of cell wall. Unlike vancomycin, additional mechanism involves disruption of membrane potential and changes cell permeability due to presence of lipophilic side chain moiety.</p></div>
<div class="block phk drugH1Div" id="F9739293"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>ss</sub>: 0.13 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~90%; primarily to albumin</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 6.6 to 9.6 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~76%); feces (&lt;1%)</p></div>
<div class="block phksp drugH1Div" id="F51160023"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: The mean AUC values were approximately 13%, 29%, and 118% higher for subjects with CrCl &gt;50 to 80 mL/minute, CrCl 30 to 50 mL/minute, and CrCl ≤30 mL/minute, respectively when compared with subjects with healthy renal function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F23671491"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Vibativ</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Vibativ</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Vibativ</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Vibativ</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Vibativ</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-29311094">
<a name="29311094"></a>Bunnell KL, Pai MP, Sikka M, et al. Pharmacokinetics of telavancin at fixed doses in normal-body-weight and obese (classes I, II, and III) adult subjects. <i>Antimicrob Agents Chemother</i>. 2018;62(4):e02475-17. doi:10.1128/AAC.02475-17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/telavancin-drug-information/abstract-text/29311094/pubmed" id="29311094" target="_blank">29311094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27721793">
<a name="27721793"></a>Chuan J, Zhang Y, He X, et al. Systematic review and meta-analysis of the efficacy and safety of telavancin for treatment of infectious disease: are we clearer? <i>Front Pharmacol</i>. 2016;7:330. doi:10.3389/fphar.2016.00330<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/telavancin-drug-information/abstract-text/27721793/pubmed" id="27721793" target="_blank">27721793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27418577">
<a name="27418577"></a>Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. <i>Clin Infect Dis</i>. 2016;63(5):e61-e111. doi:10.1093/cid/ciw353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/telavancin-drug-information/abstract-text/27418577/pubmed" id="27418577" target="_blank">27418577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21217178">
<a name="21217178"></a>Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant <i>Staphylococcus Aureus</i> infections in adults and children: executive summary. <i>Clin Infect Dis</i>. 2011;52(3):285-292.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/telavancin-drug-information/abstract-text/21217178/pubmed" id="21217178" target="_blank">21217178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20213839">
<a name="20213839"></a>Luke DR, Tomaszewski K, Damle B, Schlamm HT. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). <i>J Pharm Sci</i>. 2010;99(8):3291-3301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/telavancin-drug-information/abstract-text/20213839/pubmed" id="20213839" target="_blank">20213839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19489710">
<a name="19489710"></a>Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2009;49(1):1-45. doi:10.1086/599376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/telavancin-drug-information/abstract-text/19489710/pubmed" id="19489710" target="_blank">19489710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22867688">
<a name="22867688"></a>Nanovskaya T, Patrikeeva S, Zhan Y, et al. Transplacental Transfer of Vancomycin and Telavancin. <i>Am J Obstet Gynecol</i>. 2012;207(4):331.e1-e6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/telavancin-drug-information/abstract-text/22867688/pubmed" id="22867688" target="_blank">22867688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31372837">
<a name="31372837"></a>Niederman MS, Lee PC, Barriere SL, Barnes CN, Castaneda-Ruiz B. Telavancin in hospital-acquired and ventilator-associated pneumonia (HAP/VAP) caused by Staphylococcus aureus: post hoc analysis of 2 randomized, controlled trials. <i>Infect Dis Ther</i>. 2019;8(3):445-452. doi:10.1007/s40121-019-0255-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/telavancin-drug-information/abstract-text/31372837/pubmed" id="31372837" target="_blank">31372837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24343828">
<a name="24343828"></a>Rodvold KA, McConeghy KW. Methicillin-resistant Staphylococcus aureus therapy: past, present, and future. <i>Clin Infect Dis</i>. 2014;58(suppl 1):S20-S27. doi:10.1093/cid/cit614<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/telavancin-drug-information/abstract-text/24343828/pubmed" id="24343828" target="_blank">24343828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21148517">
<a name="21148517"></a>Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. <i>Clin Infect Dis</i>. 2011;52(1):31-40. doi:10.1093/cid/ciq031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/telavancin-drug-information/abstract-text/21148517/pubmed" id="21148517" target="_blank">21148517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24876786">
<a name="24876786"></a>Rubinstein E, Stryjewski ME, Barriere SL. Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumonia. <i>Infect Drug Resist</i>. 2014;7:129-135. doi:10.2147/IDR.S25930<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/telavancin-drug-information/abstract-text/24876786/pubmed" id="24876786" target="_blank">24876786</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spelman.1">
<a name="Spelman.1"></a>Spelman D, Baddour LM. Acute cellulitis and erysipelas in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52. doi:10.1093/cid/ciu296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/telavancin-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22416054">
<a name="22416054"></a>Stryjewski ME, Barriere SL, O'Riordan W, et al. Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections. <i>J Antimicrob Chemother</i>. 2012;67(6):1496-1502. doi:10.1093/jac/dks081<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/telavancin-drug-information/abstract-text/22416054/pubmed" id="22416054" target="_blank">22416054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16495243">
<a name="16495243"></a>Stryjewski ME, Chu VH, O’Riordan WD, et al. Telavancin Versus Standard Therapy for Treatment of Complicated Skin and Skin-Structure Infections Caused by Gram-Positive Bacteria: Fast 2 Study. <i>Antimicrob Agents Chemother</i>. 2006;50(3):862-867.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/telavancin-drug-information/abstract-text/16495243/pubmed" id="16495243" target="_blank">16495243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18444791">
<a name="18444791"></a>Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin-Structure Infections Caused by Gram-Positive Organisms. <i>Clin Infect Dis</i>. 2008;46(11):1683-1693.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/telavancin-drug-information/abstract-text/18444791/pubmed" id="18444791" target="_blank">18444791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24884578">
<a name="24884578"></a>Stryjewski ME, Lentnek A, O'Riordan W, et al. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. <i>BMC Infect Dis</i>. 2014;14:289.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/telavancin-drug-information/abstract-text/24884578/pubmed" id="24884578" target="_blank">24884578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15889357">
<a name="15889357"></a>Stryjewski ME, O’Riordan WD, Lau WK, et al. Telavancin Versus Standard Therapy for Treatment of Complicated Skin and Soft-Tissue Infections Due to Gram-Positive Bacteria. <i>Clin Infect Dis</i>. 2005;40(11):1601-1607.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/telavancin-drug-information/abstract-text/15889357/pubmed" id="15889357" target="_blank">15889357</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Vibativ (telavancin) [prescribing information]. Nashville, TN: Cumberland Pharmaceuticals Inc; December 2020.</div>
</li>
<li>
<div class="reference">
                  Vibativ (telavancin) [product monograph]. Montreal, Quebec, Canada: Pendopharm, Division of Pharmascience Inc; February 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19095213">
<a name="19095213"></a>Wilson SE, O’Riordan W, Hopkins A, et al. Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin-Structure Infections Associated With Surgical Procedures. <i>Am J Surg</i>. 2009;197(6):791-796.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/telavancin-drug-information/abstract-text/19095213/pubmed" id="19095213" target="_blank">19095213</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9535 Version 239.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
